A Phase 1, Open-label, Single-dose, Randomized Crossover Study to Evaluate the Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Subjects
Latest Information Update: 31 Dec 2021
At a glance
- Drugs Sitravatinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors BeiGene
- 31 May 2021 Status changed from recruiting to completed.
- 22 Feb 2021 Planned End Date changed from 1 Oct 2020 to 1 Apr 2021.
- 19 Aug 2020 Status changed from not yet recruiting to recruiting.